DESCRIPTION

*Drug and Alcohol Dependence* is an international journal devoted to publishing original research, scholarly reviews, commentaries, and policy analyses in the area of drug, alcohol and tobacco use and dependence. Articles range from studies of the chemistry of substances of abuse, their actions at molecular and cellular sites, *in vitro* and *in vivo* investigations of their biochemical, pharmacological and behavioural actions, laboratory-based and clinical research in humans, substance abuse treatment and prevention research, and studies employing methods from epidemiology, sociology, and economics.

The rationale for this extensive coverage is the conviction that drug, alcohol and tobacco use/dependence cannot be understood in their entirety from a single perspective and that without an understanding of other areas of research, studies by individual investigators may be limited. The goal of the journal is to provide researchers, clinicians, and policy makers access to material from all perspectives in a single journal in a format that is understandable and which has received rigorous editorial review. The hope of its editors is to promote mutual understanding of the many facets of drug abuse to the benefit of all investigators involved in drug and alcohol research, and to facilitate the transfer of scientific findings to successful treatment and prevention practices.

The accepted abbreviation for *Drug and Alcohol Dependence* for bibliographic citation is *Drug Alcohol Depend*.

*Drug and Alcohol Dependence* is currently being distributed to all the members of the College on Problems of Drug Dependence (CPDD), the oldest scientific organization in the United States concerned with research on problems of drug dependence. Members of the CPDD are provided with both the print version as well as access to the full text of the current issue and back issues dating back to Vol. 46, Issue no. 1 of the online version as a benefit of membership.

The College on Problems of Drug Dependence (CPDD), formerly the Committee on Problems of Drug Dependence, has been in existence since 1929 and is the longest standing group in the United States addressing problems of drug dependence and abuse. From 1929 until 1976, the CPDD was associated with the National Academy of Sciences, National Research Council. Since 1976, the organization has functioned as an independent body affiliated with other scientific and professional societies representing various disciplines concerned with problems of drug dependence and abuse. In 1991, the CPDD evolved into a membership organization with the new name of College on Problems of Drug Dependence.
CPDD serves as an interface among governmental, industrial and academic communities maintaining liaisons with regulatory and research agencies as well as educational, treatment, and prevention facilities in the drug abuse field. It also functions as a collaborating center of the World Health Organization.

AUDIENCE

Workers in the fields of biomedical as well as clinical, epidemiological, psychosocial, socio-cultural, educational and medico-legal research.

IMPACT FACTOR

2018: 3.466 © Clarivate Analytics Journal Citation Reports 2019

ABSTRACTING AND INDEXING

Cumulative Index to Nursing and Allied Health Literature
Research Alert
Clinical Medicine Citation Index
ETOH
BIOSIS Citation Index
Chemical Abstracts
Current Contents
Embase
PubMed/Medline
PsycINFO
Science Citation Index
Sociological Abstracts
Addiction Abstracts
Pascal Francis
Elsevier BIOBASE
HealthSTAR
Life Science Collection
Toxline
Scopus
Social Sciences Citation Index

EDITORIAL BOARD

Editor-in-Chief
Eric C. Strain, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA

Editorial Office Manager
B. McClarty, John Hopkins School of Medicine, Baltimore, Maryland, USA, Fax: 410-550-0030

Social Media Editor
Joseph J. Palamar, Langone Medical Center, New York University, New York, New York, USA

Associate Editors

Behavioral Pharmacology
Craig R. Rush, University of Kentucky College of Medicine, Lexington, KY, USA

Comorbidity, Psychiatric Epidemiology, Etiology, Nosology and Genetics
Katherine Keyes, Columbia University, New York, New York, USA

Etiology, Epidemiology, Prevention and Policy
Steve Shoptaw, UCLA Semel Institute for Neuroscience & Human Behavior, Los Angeles, California, USA
Human Psychopharmacology and Genetics
Eske Derks, QIMR Berghofer Medical Research Institute, Herston, Australia

Neuropsychopharmacology and Treatment
Lin Lu, Peking University, Beijing, China

Preclinical and Clinical Neurosciences
Linda Porrino, Wake Forest School of Medicine, Winston-Salem, North Carolina, USA

Services and Prevention, Technology Transfer, and Treatment
Jan Copeland, UNSW Australia, Randwick, New South Wales, Australia

Tobacco and Nicotine, Health Disparities, Developmental Psychopathology
Karen Cropsey, University of Alabama at Birmingham

Treatment and Services
Kyle Kampman, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, USA

Associate Editor Fellow
R.L. Tomko, Medical University of South Carolina (MUSC), Charleston, South Carolina, USA

Editorial Board
F.J. Alvarez, Valladolid, Spain
J.C. Anthony, East Lansing, Michigan, USA
M. Auriacombe, Bordeaux, France
R.L. Balster, Richmond, Virginia, USA
F.I.P.M. Bastos, Rio de Janeiro, Brazil
W.K. Bickel, Roanoke, Virginia, USA
K.L. Bluthenthal, Los Angeles, California, USA
K.T. Brady, Charleston, South Carolina, USA
A. Coop, Baltimore, Maryland, USA
J.F. Cubells, Atlanta, Georgia, USA
S. Darke, Randwick, New South Wales, Australia
K.L. Delucchi, San Francisco, California, USA
L.C. Dierker, Middletown, Connecticut, USA
M. Farré, Barcelona, Spain
M. Field, Liverpool, UK
P.M. Flynn, Fort Worth, Texas, USA
J.H.A. Franken, Rotterdam, The Netherlands
T.R. Franklin, Philadelphia, Pennsylvania, USA
D. Furr-Holden, East Lansing, Michigan, USA
B.F. Grant, Bethesda, Maryland, USA
C.A. Hanlon, Charleston, South Carolina, USA
D.S. Hasin, New York, New York, USA
D.K. Hatsukami, Minneapolis, Minnesota, USA
J.R. Havens, Lexington, Kentucky, USA
M.Y. Iguchi, Washington, District of Columbia, USA
R. Johnson, Baltimore, Maryland, USA
S.D. Johnson, St. Louis, Missouri, USA
J. Kitanaka, Hyogo, Japan
H.R. Kranzler, Philadelphia, Pennsylvania, USA
A. Kurti, Burlington, Vermont, USA
R.J. Lamb, San Antonio, Texas, USA
A.M. Leventhal, Los Angeles, California, USA
S.E. Lukas, Belmont, Massachusetts, USA
M. Medina-Mora, Mexico City, Mexico
F.G. Moeller, Richmond, Virginia, USA
M. Munafo, Bristol, UK
T.C. Napier, Chicago, Illinois, USA
K.L. Preston, Baltimore, Maryland, USA
A.J. Saxon, Seattle, Washington, USA
J.L. Sorensen, San Francisco, California, USA
J. Strange, London, UK
S.A. Strathdee, La Jolla, California, USA
D. Svikis, Richmond, Virginia, USA
J.M. Vink, Nijmegen, Netherlands
S.L. Walsh, Lexington, Kentucky, USA
J. Weafer, Chicago, Illinois, USA

Previous Editors
Robert Balster
Hans Halbach
Charles R. Schuster
Chris-Ellyn Johanson
Ian P. Stolerman
INTRODUCTION

Drug and Alcohol Dependence is an international journal devoted to publishing original research, scholarly reviews, letters to the Editor, and policy analyses in the area of drug, alcohol and tobacco use and dependence. It is sponsored by the College on Problems of Drug Dependence (CPDD), the oldest scientific organization in the United States concerned with research on addiction. The goal of its editors is to promote mutual understanding of the many facets of drug abuse to the benefit of all investigators involved in drug and alcohol research, and to facilitate the transfer of scientific findings to successful treatment and prevention practices. Drug and Alcohol Dependence is currently being distributed to all the members of CPDD.

Associate Editor Content Areas
Please click here to download details of the Associate Editor Content Areas.

Associate Editor Conflict of Interest Statements
Please click here to access the Associate Editor Conflict of Interest Statements.

Types of paper

1) Full-length Reports reporting original results of research within the field of drug, alcohol and tobacco use and dependence. A Full-length Report typically should not exceed 4000 words (for the introduction, methods, results and discussion).

2) Review Articles of specialized topics within the scope of the journal. Typically, these are critical reviews of a field of research. A Review Article typically should not exceed 6000 words for the main body of the paper (i.e., excluding references, tables and figures). Review Articles that will be substantially longer than 6000 words should be discussed with the Editor-in-Chief prior to submission.

3) Short Communications reporting on research that has progressed to the stage where a preliminary publication is appropriate. The maximum length is 2000 words plus references and illustrations. There should be not more than 2 illustrations (figure or tables).

4) Letters to the Editor will be considered by the Editors of Drug and Alcohol Dependence (DAD) on a case-by-case basis. These should address an issue consistent with the focus of the journal. If the letter is in response to a paper published in the journal, authors of the original paper will typically be given the opportunity to respond to the letter, and the Editors may decide to not publish the letter based upon that reply or may publish the reply along with the letter. Letters submitted in response to a published paper should generally be submitted within a year of the original paper. Letters may be referred for peer-review, depending upon the content. The journal generally does not publish case reports, and letters to the editor that report on a case have a high likelihood of being returned and not published. Letters are limited to 500 words, and no more than six references. Authors considering a Letter to the Editor may wish to consult with the editorial office before initiating such a submission.

5) Registered Reports (click here for more details). These submissions undergo a two-phase review process in which study rationale and methodology are considered prior to the research being undertaken.

6) Other forms of papers. The journal does not publish commentaries, individual case studies or book reviews.

Submission checklist
You can use this list to carry out a final check of your submission before you send it to the journal for review. Please check the relevant section in this Guide for Authors for more details.

Ensure that the following items are present:

One author has been designated as the corresponding author with contact details:
• E-mail address
• Full postal address

All necessary files have been uploaded:
**Manuscript:**
- Include keywords
- All figures (include relevant captions)
- All tables (including titles, description, footnotes)
- Ensure all figure and table citations in the text match the files provided
- Indicate clearly if color should be used for any figures in print
- **Graphical Abstracts / Highlights files (where applicable)**
- **Supplemental files (where applicable)**

**Further considerations**
- Manuscript has been 'spell checked' and 'grammar checked'
- All references mentioned in the Reference List are cited in the text, and vice versa
- Permission has been obtained for use of copyrighted material from other sources (including the Internet)
- A competing interests statement is provided, even if the authors have no competing interests to declare
- Journal policies detailed in this guide have been reviewed
- Referee suggestions and contact details provided, based on journal requirements

For further information, visit our [Support Center](https://www.elsevier.com/locate/drugalcdep).

**BEFORE YOU BEGIN**

**Ethics in publishing**
Please see our information pages on [Ethics in publishing](https://www.elsevier.com/locate/drugalcdep) and [Ethical guidelines for journal publication](https://www.elsevier.com/locate/drugalcdep).

**Studies in humans and animals**
If the work involves the use of human subjects, the author should ensure that the work described has been carried out in accordance with [The Code of Ethics of the World Medical Association (Declaration of Helsinki)](https://www.elsevier.com/locate/drugalcdep) for experiments involving humans. The manuscript should be in line with the [Recommendations for the Conduct, Reporting, Editing and Publication of Scholarly Work in Medical Journals](https://www.elsevier.com/locate/drugalcdep) and aim for the inclusion of representative human populations (sex, age and ethnicity) as per those recommendations. The terms *sex* and *gender* should be used correctly.

Authors should include a statement in the manuscript that informed consent was obtained for experimentation with human subjects. The privacy rights of human subjects must always be observed.

All animal experiments should comply with the [ARRIVE guidelines](https://www.elsevier.com/locate/drugalcdep) and should be carried out in accordance with the U.K. Animals (Scientific Procedures) Act, 1986 and associated guidelines, [EU Directive 2010/63/EU for animal experiments](https://www.elsevier.com/locate/drugalcdep), or the National Institutes of Health guide for the care and use of Laboratory animals (NIH Publications No. 8023, revised 1978) and the authors should clearly indicate in the manuscript that such guidelines have been followed. The sex of animals must be indicated, and where appropriate, the influence (or association) of sex on the results of the study.

**Declaration of interest**
All authors must disclose any financial and personal relationships with other people or organizations that could inappropriately influence (bias) their work. Examples of potential competing interests include employment, consultancies, stock ownership, honoraria, paid expert testimony, patent applications/registrations, and grants or other funding. Authors must disclose any interests in two places: 1. A summary declaration of interest statement in the title page file (if double-blind) or the manuscript file (if single-blind). If there are no interests to declare then please state this: 'Declarations of interest: none'. This summary statement will be ultimately published if the article is accepted. 2. Detailed disclosures as part of a separate Declaration of Interest form, which forms part of the journal's official records. It is important for potential interests to be declared in both places and that the information matches. [More information](https://www.elsevier.com/locate/drugalcdep).

**Submission declaration and verification**
Submission of an article implies that the work described has not been published previously (except in the form of an abstract, a published lecture or academic thesis, see 'Multiple, redundant or concurrent publication' for more information), that it is not under consideration for publication elsewhere, that its publication is approved by all authors and tacitly or explicitly by the responsible authorities where the work was carried out, and that, if accepted, it will not be published elsewhere in the same form, in
English or in any other language, including electronically without the written consent of the copyright-holder. To verify originality, your article may be checked by the originality detection service Crossref Similarity Check.

**Preprints**
Please note that preprints can be shared anywhere at any time, in line with Elsevier's sharing policy. Sharing your preprints e.g. on a preprint server will not count as prior publication (see 'Multiple, redundant or concurrent publication' for more information).

**Use of inclusive language**
Inclusive language acknowledges diversity, conveys respect to all people, is sensitive to differences, and promotes equal opportunities. Articles should make no assumptions about the beliefs or commitments of any reader, should contain nothing which might imply that one individual is superior to another on the grounds of race, sex, culture or any other characteristic, and should use inclusive language throughout. Authors should ensure that writing is free from bias, for instance by using ‘he or she’, ‘his/her’ instead of ‘he’ or ‘his’, and by making use of job titles that are free of stereotyping (e.g. ‘chairperson’ instead of ‘chairman’ and ‘flight attendant’ instead of ‘stewardess’).

**Contributors**
Each author is required to declare his or her individual contribution to the article: all authors must have materially participated in the research and/or article preparation, so roles for all authors should be described. The statement that all authors have approved the final article should be true and included in the disclosure.

**Changes to authorship**
Authors are expected to consider carefully the list and order of authors before submitting their manuscript and provide the definitive list of authors at the time of the original submission. Any addition, deletion or rearrangement of author names in the authorship list should be made only before the manuscript has been accepted and only if approved by the journal Editor. To request such a change, the Editor must receive the following from the corresponding author: (a) the reason for the change in author list and (b) written confirmation (e-mail, letter) from all authors that they agree with the addition, removal or rearrangement. In the case of addition or removal of authors, this includes confirmation from the author being added or removed. Only in exceptional circumstances will the Editor consider the addition, deletion or rearrangement of authors after the manuscript has been accepted. While the Editor considers the request, publication of the manuscript will be suspended. If the manuscript has already been published in an online issue, any requests approved by the Editor will result in a corrigendum.

**Reporting clinical trials**
Randomized controlled trials should be presented according to the CONSORT guidelines. At manuscript submission, authors must provide the CONSORT checklist accompanied by a flow diagram that illustrates the progress of patients through the trial, including recruitment, enrollment, randomization, withdrawal and completion, and a detailed description of the randomization procedure. The CONSORT checklist and template flow diagram are available online.

Reporting guidelines have also been developed for a number of other study designs:

1. **Initiative**  
   **Type of study**  
   **Source**  
   CONSORT randomized controlled trials  
   [http://www.consort-statement.org](http://www.consort-statement.org)  
   STARD studies of diagnostic accuracy  
   PRISMA systematic reviews and meta-analyses  
   [http://www.prisma-statement.org](http://www.prisma-statement.org)  
   MOOSE meta-analyses of observational studies in epidemiology  
   [http://www.strobe-statement.org](http://www.strobe-statement.org)  
   STROBE observational studies in epidemiology  
   [http://www.strobe-statement.org](http://www.strobe-statement.org)  
   MOOSE meta-analyses of observational studies in epidemiology  
   [http://www.prisma-statement.org](http://www.prisma-statement.org)  
   STROBE observational studies in epidemiology  
   [http://www.strobe-statement.org](http://www.strobe-statement.org)

**Registration of clinical trials**
Registration in a public trials registry is a condition for publication of clinical trials in this journal in accordance with International Committee of Medical Journal Editors recommendations. Trials must register at or before the onset of patient enrolment. The clinical trial registration number should be included at the end of the abstract of the article. A clinical trial is defined as any research study that prospectively assigns human participants or groups of humans to one or more
health-related interventions to evaluate the effects of health outcomes. Health-related interventions include any intervention used to modify a biomedical or health-related outcome (for example drugs, surgical procedures, devices, behavioural treatments, dietary interventions, and process-of-care changes). Health outcomes include any biomedical or health-related measures obtained in patients or participants, including pharmacokinetic measures and adverse events. Purely observational studies (those in which the assignment of the medical intervention is not at the discretion of the investigator) will not require registration.

**Author Disclosures**

As is widely acknowledged within medical publishing, the integrity of articles published in *Drug and Alcohol Dependence* depends in part on how well the Journal handles author disclosure. As described in detail below, authors are requested to provide three mandatory and one optional author disclosure sections; please do not include them in the manuscripts. The author disclosures will be automatically incorporated in the PDF builder of the online submission system. These statements will appear in the journal article if the paper is accepted. It is highly recommended that authors prepare these author disclosures prior to going online to submit the paper.

The sequence for the Author Disclosures section should be **Role of Funding Source** (required; default text "Nothing declared"), **Contributors** (should always state something when more than one author), **Conflict of Interest** (required; default text "No conflict declared") and **Acknowledgements** (optional).

The four statements should not be numbered

- Headings should be in bold
- No white space between the heading and the text
- Same font size as the references

**Article transfer service**

This journal is part of our Article Transfer Service. This means that if the Editor feels your article is more suitable in one of our other participating journals, then you may be asked to consider transferring the article to one of those. If you agree, your article will be transferred automatically on your behalf with no need to reformat. Please note that your article will be reviewed again by the new journal.

**Copyright**

Upon acceptance of an article, authors will be asked to complete a 'Journal Publishing Agreement' (see more information on this). An e-mail will be sent to the corresponding author confirming receipt of the manuscript together with a 'Journal Publishing Agreement' form or a link to the online version of this agreement.

Subscribers may reproduce tables of contents or prepare lists of articles including abstracts for internal circulation within their institutions. *Permission* of the Publisher is required for resale or distribution outside the institution and for all other derivative works, including compilations and translations. If excerpts from other copyrighted works are included, the author(s) must obtain written permission from the copyright owners and credit the source(s) in the article. Elsevier has preprinted forms for use by authors in these cases.

For gold open access articles: Upon acceptance of an article, authors will be asked to complete an 'Exclusive License Agreement' (more information). Permitted third party reuse of gold open access articles is determined by the author's choice of user license.

**Author rights**

As an author you (or your employer or institution) have certain rights to reuse your work. More information.

*Elsevier supports responsible sharing*

Find out how you can share your research published in Elsevier journals.
**Role of the funding source**
You are requested to identify who provided financial support for the conduct of the research and/or preparation of the article and to briefly describe the role of the sponsor(s), if any, in study design; in the collection, analysis and interpretation of data; in the writing of the report; and in the decision to submit the article for publication. If the funding source(s) had no such involvement then this should be stated.

**Funding body agreements and policies**
Elsevier has established a number of agreements with funding bodies which allow authors to comply with their funder's open access policies. Some funding bodies will reimburse the author for the gold open access publication fee. Details of existing agreements are available online. After acceptance, open access papers will be published under a noncommercial license. For authors requiring a commercial CC BY license, you can apply after your manuscript is accepted for publication.

**Open access**
This journal offers authors a choice in publishing their research:

**Subscription**
- Articles are made available to subscribers as well as developing countries and patient groups through our universal access programs.
- No open access publication fee payable by authors.
- The Author is entitled to post the accepted manuscript in their institution's repository and make this public after an embargo period (known as green Open Access). The published journal article cannot be shared publicly, for example on ResearchGate or Academia.edu, to ensure the sustainability of peer-reviewed research in journal publications. The embargo period for this journal can be found below.

**Gold open access**
- Articles are freely available to both subscribers and the wider public with permitted reuse.
- A gold open access publication fee is payable by authors or on their behalf, e.g. by their research funder or institution.

Regardless of how you choose to publish your article, the journal will apply the same peer review criteria and acceptance standards.

For gold open access articles, permitted third party (re)use is defined by the following Creative Commons user licenses:

**Creative Commons Attribution-NonCommercial-NoDerivs (CC BY-NC-ND)**
For non-commercial purposes, lets others distribute and copy the article, and to include in a collective work (such as an anthology), as long as they credit the author(s) and provided they do not alter or modify the article.

The gold open access publication fee for this journal is **USD 3350**, excluding taxes. Learn more about Elsevier's pricing policy: [https://www.elsevier.com/openaccesspricing](https://www.elsevier.com/openaccesspricing).

**Green open access**
Authors can share their research in a variety of different ways and Elsevier has a number of green open access options available. We recommend authors see our open access page for further information. Authors can also self-archive their manuscripts immediately and enable public access from their institution's repository after an embargo period. This is the version that has been accepted for publication and which typically includes author-incorporated changes suggested during submission, peer review and in editor-author communications. Embargo period: For subscription articles, an appropriate amount of time is needed for journals to deliver value to subscribing customers before an article becomes freely available to the public. This is the embargo period and it begins from the date the article is formally published online in its final and fully citable form. Find out more.

This journal has an embargo period of 12 months.

**Elsevier Researcher Academy**
Researcher Academy is a free e-learning platform designed to support early and mid-career researchers throughout their research journey. The "Learn" environment at Researcher Academy offers several interactive modules, webinars, downloadable guides and resources to guide you through the process of writing for research and going through peer review. Feel free to use these free resources to improve your submission and navigate the publication process with ease.
Language (usage and editing services)
Please write your text in good English (American or British usage is accepted, but not a mixture of these). Authors who feel their English language manuscript may require editing to eliminate possible grammatical or spelling errors and to conform to correct scientific English may wish to use the English Language Editing service available from Elsevier's Author Services.

Submission
Our online submission system guides you stepwise through the process of entering your article details and uploading your files. The system converts your article files to a single PDF file used in the peer-review process. Editable files (e.g., Word, LaTeX) are required to typeset your article for final publication. All correspondence, including notification of the Editor's decision and requests for revision, is sent by e-mail.

Submit your article
Please submit your article via http://ees.elsevier.com/dad/.

Referees
Please submit, with the manuscript, the names, addresses and e-mail addresses of a minimum of three potential referees. Note that the editor retains the sole right to decide whether or not the suggested reviewers are used.

PREPARATION

Use of word processing software
It is important that the file be saved in the native format of the word processor used. The text should be in single-column format. Keep the layout of the text as simple as possible. Most formatting codes will be removed and replaced on processing the article. In particular, do not use the word processor's options to justify text or to hyphenate words. However, do use bold face, italics, subscripts, superscripts etc. When preparing tables, if you are using a table grid, use only one grid for each individual table and not a grid for each row. If no grid is used, use tabs, not spaces, to align columns. The electronic text should be prepared in a way very similar to that of conventional manuscripts (see also the Guide to Publishing with Elsevier). Note that source files of figures, tables and text graphics will be required whether or not you embed your figures in the text. See also the section on Electronic artwork.

To avoid unnecessary errors you are strongly advised to use the 'spell-check' and 'grammar-check' functions of your word processor.

Article structure
Subdivision - numbered sections
Divide your article into clearly defined and numbered sections. Subsections should be numbered 1.1 (then 1.1.1, 1.1.2, ...), 1.2, etc. (the abstract is not included in section numbering). Use this numbering also for internal cross-referencing: do not just refer to 'the text'. Any subsection may be given a brief heading. Each heading should appear on its own separate line.

Introduction
State the objectives of the work and provide an adequate background, avoiding a detailed literature survey or a summary of the results.

Material and methods
Provide sufficient details to allow the work to be reproduced by an independent researcher. Methods that are already published should be summarized, and indicated by a reference. If quoting directly from a previously published method, use quotation marks and also cite the source. Any modifications to existing methods should also be described.

Results
Results should be clear and concise.

Discussion
This should explore the significance of the results of the work, not repeat them. A combined Results and Discussion section is often appropriate. Avoid extensive citations and discussion of published literature.

Conclusions
The main conclusions of the study may be presented in a short Conclusions section, which may stand alone or form a subsection of a Discussion or Results and Discussion section.
Essential title page information

• **Title.** Concise and informative. Titles are often used in information-retrieval systems. Avoid abbreviations and formulae where possible.

• **Author names and affiliations.** Please clearly indicate the given name(s) and family name(s) of each author and check that all names are accurately spelled. You can add your name between parentheses in your own script behind the English transliteration. Present the authors' affiliation addresses (where the actual work was done) below the names. Indicate all affiliations with a lower-case superscript letter immediately after the author's name and in front of the appropriate address. Provide the full postal address of each affiliation, including the country name and, if available, the e-mail address of each author.

• **Corresponding author.** Clearly indicate who will handle correspondence at all stages of refereeing and publication, also post-publication. This responsibility includes answering any future queries about Methodology and Materials. **Ensure that the e-mail address is given and that contact details are kept up to date by the corresponding author.**

• **Present/permanent address.** If an author has moved since the work described in the article was done, or was visiting at the time, a 'Present address' (or 'Permanent address') may be indicated as a footnote to that author's name. The address at which the author actually did the work must be retained as the main, affiliation address. Superscript Arabic numerals are used for such footnotes.

**Highlights**

Highlights are mandatory for this journal as they help increase the discoverability of your article via search engines. They consist of a short collection of bullet points that capture the novel results of your research as well as new methods that were used during the study (if any). Please have a look at the examples here: [example Highlights](#).

Highlights should be submitted in a separate editable file in the online submission system. Please use 'Highlights' in the file name and include 3 to 5 bullet points (maximum 85 characters, including spaces, per bullet point).

**Structured abstract**

A structured abstract, by means of appropriate headings, should provide the context or background for the research and should state its purpose, basic procedures (selection of study subjects or laboratory animals, observational and analytical methods), main findings (giving specific effect sizes and their statistical significance, if possible), and principal conclusions. It should emphasize new and important aspects of the study or observations.

Abstracts should be structured with specific sections describing the background, methods, results and conclusions with a maximum of 250 words.

**Graphical abstract**

Although a graphical abstract is optional, its use is encouraged as it draws more attention to the online article. The graphical abstract should summarize the contents of the article in a concise, pictorial form designed to capture the attention of a wide readership. Graphical abstracts should be submitted as a separate file in the online submission system. Image size: Please provide an image with a minimum of 531 × 1328 pixels (h × w) or proportionally more. The image should be readable at a size of 5 × 13 cm using a regular screen resolution of 96 dpi. Preferred file types: TIFF, EPS, PDF or MS Office files. You can view [Example Graphical Abstracts](#) on our information site.

Authors can make use of Elsevier's [Illustration Services](#) to ensure the best presentation of their images and in accordance with all technical requirements.

**Keywords**

Immediately after the abstract, provide a maximum of 6 keywords, using American spelling and avoiding general and plural terms and multiple concepts (avoid, for example, 'and', 'of'). Be sparing with abbreviations: only abbreviations firmly established in the field may be eligible. These keywords will be used for indexing purposes.

**Abbreviations**

Define abbreviations that are not standard in this field at their first mention in the text. Ensure consistency of abbreviations throughout the article.

**Formatting of funding sources**

List funding sources in this standard way to facilitate compliance to funder's requirements:
Funding: This work was supported by the National Institutes of Health [grant numbers xxxx, yyyy]; the Bill & Melinda Gates Foundation, Seattle, WA [grant number zzzz]; and the United States Institutes of Peace [grant number aaaa].

It is not necessary to include detailed descriptions on the program or type of grants and awards. When funding is from a block grant or other resources available to a university, college, or other research institution, submit the name of the institute or organization that provided the funding.

If no funding has been provided for the research, please include the following sentence:

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

Units
Follow internationally accepted rules and conventions: use the international system of units (SI). If other units are mentioned, please give their equivalent in SI.

Footnotes
Footnotes should be used sparingly. Number them consecutively throughout the article. Many word processors can build footnotes into the text, and this feature may be used. Otherwise, please indicate the position of footnotes in the text and list the footnotes themselves separately at the end of the article. Do not include footnotes in the Reference list.

Artwork
Electronic artwork
General points
• Make sure you use uniform lettering and sizing of your original artwork.
• Embed the used fonts if the application provides that option.
• Aim to use the following fonts in your illustrations: Arial, Courier, Times New Roman, Symbol, or use fonts that look similar.
• Number the illustrations according to their sequence in the text.
• Use a logical naming convention for your artwork files.
• Provide captions to illustrations separately.
• Size the illustrations close to the desired dimensions of the published version.
• Submit each illustration as a separate file.

A detailed guide on electronic artwork is available.

You are urged to visit this site; some excerpts from the detailed information are given here.

Formats
If your electronic artwork is created in a Microsoft Office application (Word, PowerPoint, Excel) then please supply 'as is' in the native document format. Regardless of the application used other than Microsoft Office, when your electronic artwork is finalized, please 'Save as' or convert the images to one of the following formats (note the resolution requirements for line drawings, halftones, and line/halftone combinations given below):
EPS (or PDF): Vector drawings, embed all used fonts.
TIFF (or JPEG): Color or grayscale photographs (halftones), keep to a minimum of 300 dpi.
TIFF (or JPEG): Bitmapped (pure black & white pixels) line drawings, keep to a minimum of 1000 dpi.
TIFF (or JPEG): Combinations bitmapped line/half-tone (color or grayscale), keep to a minimum of 500 dpi.

Please do not:
• Supply files that are optimized for screen use (e.g., GIF, BMP, PICT, WPG); these typically have a low number of pixels and limited set of colors;
• Supply files that are too low in resolution;
• Submit graphics that are disproportionately large for the content.

Color artwork
Please make sure that artwork files are in an acceptable format (TIFF (or JPEG), EPS (or PDF), or MS Office files) and with the correct resolution. If, together with your accepted article, you submit usable color figures then Elsevier will ensure, at no additional charge, that these figures will appear in color online (e.g., ScienceDirect and other sites) regardless of whether or not these illustrations are reproduced in color in the printed version.
information regarding the costs from Elsevier after receipt of your accepted article. Please indicate your preference for color: in print or online only. Further information on the preparation of electronic artwork.

Illustration services
Elsevier's Author Services offers Illustration Services to authors preparing to submit a manuscript but concerned about the quality of the images accompanying their article. Elsevier's expert illustrators can produce scientific, technical and medical-style images, as well as a full range of charts, tables and graphs. Image 'polishing' is also available, where our illustrators take your image(s) and improve them to a professional standard. Please visit the website to find out more.

Figure captions
Ensure that each illustration has a caption. Supply captions separately, not attached to the figure. A caption should comprise a brief title (not on the figure itself) and a description of the illustration. Keep text in the illustrations themselves to a minimum but explain all symbols and abbreviations used.

Tables
Please submit tables as editable text and not as images. Tables can be placed either next to the relevant text in the article, or on separate page(s) at the end. Number tables consecutively in accordance with their appearance in the text and place any table notes below the table body. Be sparing in the use of tables and ensure that the data presented in them do not duplicate results described elsewhere in the article. Please avoid using vertical rules and shading in table cells.

References
Citation in text
Please ensure that every reference cited in the text is also present in the reference list (and vice versa). Any references cited in the abstract must be given in full. Unpublished results and personal communications are not recommended in the reference list, but may be mentioned in the text. If these references are included in the reference list they should follow the standard reference style of the journal and should include a substitution of the publication date with either 'Unpublished results' or 'Personal communication'. Citation of a reference as 'in press' implies that the item has been accepted for publication.

Reference links
Increased discoverability of research and high quality peer review are ensured by online links to the sources cited. In order to allow us to create links to abstracting and indexing services, such as Scopus, CrossRef and PubMed, please ensure that data provided in the references are correct. Please note that incorrect surnames, journal/book titles, publication year and pagination may prevent link creation. When copying references, please be careful as they may already contain errors. Use of the DOI is highly encouraged.

A DOI is guaranteed never to change, so you can use it as a permanent link to any electronic article. An example of a citation using DOI for an article not yet in an issue is: VanDecar J.C., Russo R.M., James D.E., Ambeh W.B., Franke M. (2003). Aseismic continuation of the Lesser Antilles slab beneath northeastern Venezuela. Journal of Geophysical Research, https://doi.org/10.1029/2001JB000884. Please note the format of such citations should be in the same style as all other references in the paper.

Web references
As a minimum, the full URL should be given and the date when the reference was last accessed. Any further information, if known (DOI, author names, dates, reference to a source publication, etc.), should also be given. Web references can be listed separately (e.g., after the reference list) under a different heading if desired, or can be included in the reference list.

Data references
This journal encourages you to cite underlying or relevant datasets in your manuscript by citing them in your text and including a data reference in your Reference List. Data references should include the following elements: author name(s), dataset title, data repository, version (where available), year, and global persistent identifier. Add [dataset] immediately before the reference so we can properly identify it as a data reference. The [dataset] identifier will not appear in your published article.

References in a special issue
Please ensure that the words 'this issue' are added to any references in the list (and any citations in the text) to other articles in the same Special Issue.
Reference management software

Most Elsevier journals have their reference template available in many of the most popular reference management software products. These include all products that support Citation Style Language styles, such as Mendeley. Using citation plug-ins from these products, authors only need to select the appropriate journal template when preparing their article, after which citations and bibliographies will be automatically formatted in the journal’s style. If no template is yet available for this journal, please follow the format of the sample references and citations as shown in this Guide. If you use reference management software, please ensure that you remove all field codes before submitting the electronic manuscript. More information on how to remove field codes from different reference management software.

Users of Mendeley Desktop can easily install the reference style for this journal by clicking the following link:

When preparing your manuscript, you will then be able to select this style using the Mendeley plug-ins for Microsoft Word or LibreOffice.

Reference style

Text: All citations in the text should refer to:
1. Single author: the author’s name (without initials, unless there is ambiguity) and the year of publication;
2. Two authors: both authors' names and the year of publication;
3. Three or more authors: first author's name followed by 'et al.' and the year of publication.

Citations may be made directly (or parenthetically). Groups of references should be listed first alphabetically, then chronologically.

Examples: 'as demonstrated (Allan, 2000a, 2000b, 1999; Allan and Jones, 1999). Kramer et al. (2010) have recently shown ....'

List: References should be arranged first alphabetically and then further sorted chronologically if necessary. Abbreviated words in journal titles should be followed by a full stop. More than one reference from the same author(s) in the same year must be identified by the letters 'a', 'b', 'c', etc., placed after the year of publication.

Examples:
Reference to a journal publication:

Reference to a book:

Reference to a chapter in an edited book:

Reference to a dataset:

Journal Abbreviations Source

Abbreviations of journal titles should conform to those used by Index Medicus (http://www.nlm.nih.gov/tsd/serials/lji.html).

Video

Elsevier accepts video material and animation sequences to support and enhance your scientific research. Authors who have video or animation files that they wish to submit with their article are strongly encouraged to include links to these within the body of the article. This can be done in the same way as a figure or table by referring to the video or animation content and noting in the body text where it should be placed. All submitted files should be properly labeled so that they directly relate to the video file's content. In order to ensure that your video or animation material is directly usable, please provide the file in one of our recommended file formats with a preferred maximum size of 150 MB per file, 1 GB in total. Video and animation files supplied will be published online in the electronic version of your article in Elsevier Web products, including ScienceDirect. Please supply 'stills' with your files: you can choose any frame from the video or animation or make a separate image. These will be used instead of standard icons and will personalize the link to your video data. For
more detailed instructions please visit our video instruction pages. Note: since video and animation cannot be embedded in the print version of the journal, please provide text for both the electronic and the print version for the portions of the article that refer to this content.

Data visualization
Include interactive data visualizations in your publication and let your readers interact and engage more closely with your research. Follow the instructions here to find out about available data visualization options and how to include them with your article.

Supplementary material
Supplementary material such as applications, images and sound clips, can be published with your article to enhance it. Submitted supplementary items are published exactly as they are received (Excel or PowerPoint files will appear as such online). Please submit your material together with the article and supply a concise, descriptive caption for each supplementary file. If you wish to make changes to supplementary material during any stage of the process, please make sure to provide an updated file. Do not annotate any corrections on a previous version. Please switch off the 'Track Changes' option in Microsoft Office files as these will appear in the published version.

Research data
This journal encourages and enables you to share data that supports your research publication where appropriate, and enables you to interlink the data with your published articles. Research data refers to the results of observations or experimentation that validate research findings. To facilitate reproducibility and data reuse, this journal also encourages you to share your software, code, models, algorithms, protocols, methods and other useful materials related to the project.

Below are a number of ways in which you can associate data with your article or make a statement about the availability of your data when submitting your manuscript. If you are sharing data in one of these ways, you are encouraged to cite the data in your manuscript and reference list. Please refer to the "References" section for more information about data citation. For more information on depositing, sharing and using research data and other relevant research materials, visit the research data page.

Data linking
If you have made your research data available in a data repository, you can link your article directly to the dataset. Elsevier collaborates with a number of repositories to link articles on ScienceDirect with relevant repositories, giving readers access to underlying data that gives them a better understanding of the research described.

There are different ways to link your datasets to your article. When available, you can directly link your dataset to your article by providing the relevant information in the submission system. For more information, visit the database linking page.

For supported data repositories a repository banner will automatically appear next to your published article on ScienceDirect.

In addition, you can link to relevant data or entities through identifiers within the text of your manuscript, using the following format: Database: xxxx (e.g., TAIR: AT1G01020; CCDC: 734053; PDB: 1XFN).

Mendeley Data
This journal supports Mendeley Data, enabling you to deposit any research data (including raw and processed data, video, code, software, algorithms, protocols, and methods) associated with your manuscript in a free-to-use, open access repository. During the submission process, after uploading your manuscript, you will have the opportunity to upload your relevant datasets directly to Mendeley Data. The datasets will be listed and directly accessible to readers next to your published article online.

For more information, visit the Mendeley Data for journals page.

Data statement
To foster transparency, we encourage you to state the availability of your data in your submission. This may be a requirement of your funding body or institution. If your data is unavailable to access or unsuitable to post, you will have the opportunity to indicate why during the submission process, for example by stating that the research data is confidential. The statement will appear with your published article on ScienceDirect. For more information, visit the Data Statement page.
AFTER ACCEPTANCE

**Online proof correction**

Corresponding authors will receive an e-mail with a link to our online proofing system, allowing annotation and correction of proofs online. The environment is similar to MS Word: in addition to editing text, you can also comment on figures/tables and answer questions from the Copy Editor. Web-based proofing provides a faster and less error-prone process by allowing you to directly type your corrections, eliminating the potential introduction of errors.

If preferred, you can still choose to annotate and upload your edits on the PDF version. All instructions for proofing will be given in the e-mail we send to authors, including alternative methods to the online version and PDF.

We will do everything possible to get your article published quickly and accurately. Please use this proof only for checking the typesetting, editing, completeness and correctness of the text, tables and figures. Significant changes to the article as accepted for publication will only be considered at this stage with permission from the Editor. It is important to ensure that all corrections are sent back to us in one communication. Please check carefully before replying, as inclusion of any subsequent corrections cannot be guaranteed. Proofreading is solely your responsibility.

**Offprints**

The corresponding author will, at no cost, receive a customized Share Link providing 50 days free access to the final published version of the article on ScienceDirect. The Share Link can be used for sharing the article via any communication channel, including email and social media. For an extra charge, paper offprints can be ordered via the offprint order form which is sent once the article is accepted for publication. Both corresponding and co-authors may order offprints at any time via Elsevier's Author Services. Corresponding authors who have published their article gold open access do not receive a Share Link as their final published version of the article is available open access on ScienceDirect and can be shared through the article DOI link.

**AUTHOR INQUIRIES**

Visit the Elsevier Support Center to find the answers you need. Here you will find everything from Frequently Asked Questions to ways to get in touch.

You can also check the status of your submitted article or find out when your accepted article will be published.

© Copyright 2018 Elsevier | https://www.elsevier.com